Atopic dermatitis is a condition that commonly arises in early childhood and is more frequent in people with a family history of the disease. The most common symptom is a rash frequently appearing on the arms and behind the knees, but also appearing anywhere, including even on the face. Commonly used treatment for mild conditions includes avoiding harsh soaps and other irritants. Certain type of creams or ointments may provide relief from the itching in mild cases. In moderate to severe cases, steroids, antihistamines and topical antiseptics are used as allopathic treatment. Recent treatments and clinical trials for severe patients are include administrating anti-IL-4Rα monoclonal antibodies. This strategy is very effective against severe atopic dermatitis, but immunogenicity to the medication is highly possible in long-term therapy.
TeraImmune develops a novel therapeutic for atopic dermatitis with a whole new approach. TeraImmune expects to develop a biological strategy to recruit regulatory T cells (Tregs) topically at an affected area with minimal adverse effect.